Cidara Therapeutics, Inc. (NASDAQ:CDTX) CEO Jeffrey Stein bought 7,350 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were bought at an average price of $6.79 per share, with a total value of $49,906.50. Following the completion of the transaction, the chief executive officer now owns 51,851 shares in the company, valued at approximately $352,068.29. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Cidara Therapeutics, Inc. (CDTX) opened at 6.65 on Wednesday. Cidara Therapeutics, Inc. has a 12-month low of $5.60 and a 12-month high of $12.95. The firm’s market cap is $112.14 million. The stock’s 50 day moving average price is $6.85 and its 200-day moving average price is $7.02.
Cidara Therapeutics (NASDAQ:CDTX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by ($0.08). Equities research analysts anticipate that Cidara Therapeutics, Inc. will post ($3.62) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Cidara Therapeutics, Inc. (CDTX) CEO Jeffrey Stein Purchases 7,350 Shares” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/2888562/cidara-therapeutics-inc-cdtx-ceo-jeffrey-stein-purchases-7350-shares.html.
A number of analysts have recently weighed in on CDTX shares. Wedbush reiterated an “outperform” rating and set a $13.00 target price on shares of Cidara Therapeutics in a research report on Tuesday, May 16th. ValuEngine downgraded Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Cantor Fitzgerald set a $11.00 target price on Cidara Therapeutics and gave the company a “buy” rating in a research report on Monday, June 5th. Zacks Investment Research upgraded Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research report on Monday, June 19th. Finally, WBB Securities upgraded Cidara Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Cidara Therapeutics has an average rating of “Buy” and a consensus target price of $13.14.
A number of large investors have recently bought and sold shares of CDTX. Teachers Advisors LLC boosted its stake in Cidara Therapeutics by 17.5% during the fourth quarter. Teachers Advisors LLC now owns 16,524 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 2,458 shares during the period. Bank of New York Mellon Corp boosted its stake in Cidara Therapeutics by 6.7% during the first quarter. Bank of New York Mellon Corp now owns 42,350 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 2,647 shares during the period. JPMorgan Chase & Co. boosted its stake in Cidara Therapeutics by 455.6% during the first quarter. JPMorgan Chase & Co. now owns 25,639 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 21,024 shares during the period. Spark Investment Management LLC bought a new stake in Cidara Therapeutics during the first quarter valued at $227,000. Finally, TIAA CREF Investment Management LLC boosted its stake in Cidara Therapeutics by 4.9% during the first quarter. TIAA CREF Investment Management LLC now owns 39,065 shares of the biotechnology company’s stock valued at $305,000 after buying an additional 1,840 shares during the period. 66.10% of the stock is owned by institutional investors.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.